Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Dr Tryfonia Mainou-Fowler.

Newcastle AuthorsTitleYearFull text
Dr Nicola Sunter
Dr Helen Marr
Dr Andrew Hall
Dr Tryfonia Mainou-Fowler
Professor Graham Jackson
et al.
Common variation at 12q24.13 (OAS3) influences chronic lymphocytic leukemia risk2015
Dr Nicola Sunter
Dr Andrew Hall
Dr Tryfonia Mainou-Fowler
Professor Graham Jackson
Professor James Allan
et al.
A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia2014
Dr Rachel Crossland
Dr Tryfonia Mainou-Fowler
Dr Michal Sieniawski
Dr Christopher Bacon
Dr Vikki Rand
et al.
High BACH2 gene Expression Is an Indicator of Poor Prognosis in Adult Diffuse Large B-Cell Lymphoma Treated with R-CHOP2014
Dr Rachel Crossland
Dr Michal Sieniawski
Parimala Saminathan
Dr Tryfonia Mainou-Fowler
MicroRNAs are suitable for assessment as biomarkers from formalin-fixed paraffin-embedded tissue, and miR-24 represents an appropriate reference microRNA for diffuse large B-cell lymphoma studies2013
Dr Rachel Crossland
Dr Michal Sieniawski
Dr Brian Angus
Professor Stephen Proctor
Dr Paul Milne
et al.
Prognostic significance of immunohistochemistry-based markers and algorithms in immunochemotherapy-treated diffuse large B-cell lymphoma patients2013
Professor Stephen Proctor
Dr Jennifer Wilkinson
Gillian Watson
Dr Helen Lucraft
Dr Tryfonia Mainou-Fowler
et al.
Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study2012
Professor Stephen Proctor
Dr Jennifer Wilkinson
Dr Helen Lucraft
Dr Richard McNally
Dr Tryfonia Mainou-Fowler
et al.
Comparative clinical responses of three chemotherapy schedules (VEPEMB, ABVD, CLVPP) in 175 Hodgkin Lymphoma patients over 60ys evaluated as part of the Shield (Hodgkin elderly) Study2011
Dr Rachel Crossland
Dr Michal Sieniawski
Dr Brian Angus
Dr Susan Proctor
Kate McCabe
et al.
Mature microRNAs of the miR-17-92 cluster predict for disease outcome in diffuse large B-cell lymphoma (DLBCL) patients treated with CHOP-R immunochemotherapy2011
Dr Tryfonia Mainou-Fowler
Dr Gordon Strathdee
Methylation markers identify high risk patients in IGHV mutated chronic lymphocytic leukemia2011
Dr Rachel Crossland
Dr Kim Pearce
Dr Nicola Sunter
Dr Tryfonia Mainou-Fowler
MicroRNAs in B-cell chronic lymphocytic leukaemia (B-CLL): mature microRNAs of the miR-17-92 cluster predict for treatment free survival (TFS) in patients with B-CLL2011
Dr sarah Johnson
Clark Crawford
Dr Evan Mulligan
Dr Jonathan Wallis
Dr Tryfonia Mainou-Fowler
et al.
Mitoxantrone in combination with an inhibitor of DNA-dependent kinase: a potential therapy for high risk B-cell chronic lymphocytic leukaemia2011
Dr Rachel Crossland
Dr John Anderson
Dr Brian Angus
Professor Stephen Proctor
Dr Stephen Crosier
et al.
A 9 series microRNA signature differentiates between germinal centre and activated B-cell-like diffuse large B-cell lymphoma cell lines2010
Dr Rachel Crossland
Dr John Anderson
Dr Brian Angus
Professor Stephen Proctor
Dr Stephen Crosier
et al.
A 9 series microRNA signature differentiates between germinal centre and activated B-cell-like diffuse large B-cell lymphoma cell lines2010
Dr Rachel Crossland
Professor Stephen Proctor
Dr Brian Angus
Dr Stephen Crosier
Dr John Anderson
et al.
A 9 series microRNA signature differentiates between germinal centre and activated B-cell-like diffuse large B-cell lymphoma cell lines2010
Dr Nicola Sunter
Dr Andrew Hall
Dr Tryfonia Mainou-Fowler
Professor Graham Jackson
Professor James Allan
et al.
Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk2010
Dr Rachel Crossland
Professor Stephen Proctor
Professor James Allan
Dr Tryfonia Mainou-Fowler
Mature MicroRNAs Mir-18,-19a,-19b,-17-5p and-92 of the Mir-17-92 Cluster Predict for Treatment Free Survival In Patients with Chronic Lymphocytic Leukaemia2010
Dr sarah Johnson
Dr Tryfonia Mainou-Fowler
Professor barbara Durkacz
Dr Elaine Willmore
Mitoxantrone in combination with an inhibitor of DNA-dependent protein kinase: A potential therapy for poor risk B-cell chronic lymphocytic leukaemia2010
Professor James Allan
Dr Nicola Sunter
Dr Andrew Hall
Dr Christopher Bacon
Jonathan Pointon
et al.
Variant IRF4/MUM1 associates with CD38 status and treatment-free survival in chronic lymphocytic leukaemia2010
Dr Michal Sieniawski
Dr Malcolm Farrow
Elaine Zhao
Dr Jennifer Wilkinson
Dr Tryfonia Mainou-Fowler
et al.
A Novel Bayesian Prognostic Index for Diffuse Large B-Cell Lymphoma: A New Powerful Tool for Prediction Of Outcome2009
Dr John Anderson
Lynne Overman
Dr Katrina Wood
Professor Stephen Proctor
Dr Stephen Crosier
et al.
Immunophenotyping of diffuse large B-cell lymphoma (DLBCL) defines multiple sub-groups of germinal centre-like tumours displaying different survival characteristics2009
Professor James Allan
Dr Nicola Sunter
Dr Andrew Hall
Dr Tryfonia Mainou-Fowler
Professor Graham Jackson
et al.
A Common Genetic Variant in the 3'UTR of IRF4/MUM1 Associates with Risk of Disease and Poor Prognosis in Chronic Lymphocytic Leukaemia2008
Dr Nicola Sunter
Dr Andrew Hall
Dr Tryfonia Mainou-Fowler
Professor Graham Jackson
Professor James Allan
et al.
A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia2008
Dr Tryfonia Mainou-Fowler
Lynne Overman
Dr Katrina Wood
Dr Brian Angus
Professor Stephen Proctor
et al.
A new subtype-specific monoclonal antibody for IAP-survivin identifies high-risk patients with diffuse large B-cell lymphoma and improves the prognostic value of bcl-22008
Dr Tryfonia Mainou-Fowler
Professor Stephen Proctor
Dr John Anderson
CD31 density is a new risk factor for patients with B-cell chronic lymphocytic leukaemia2008
Dr Tryfonia Mainou-Fowler
Dr John Anderson
Professor Stephen Proctor
CD31 density is a novel risk factor for patients with B-cell chronic lymphocytic leukaemia2008
Dr Elaine Willmore
Dr sarah Johnson
Dr Tryfonia Mainou-Fowler
Professor Graham Jackson
Dr Celine Cano
et al.
DNA-dependent protein kinase is a therapeutic target and an indicator of poor prognosis in B-cell chronic lymphocytic leukemia2008
Dr Elaine Willmore
Dr sarah Johnson
Clark Crawford
Dr Tryfonia Mainou-Fowler
Professor Graham Jackson
et al.
DNA-Dependent Protein Kinase Is a Therapeutic Target in Poor Prognosis B-Cell Chronic Lymphocytic Leukemia2008
Dr Michal Sieniawski
Dr Jennifer Wilkinson
Dr Anne Lennard
Dr Helen Lucraft
Dr Tryfonia Mainou-Fowler
et al.
Duration of First Remission in Diffuse Large B-Cell Lymphoma (DLBCL) Define Groups of Patients with Different Overall Survival Which Cannot Be Entirely Distinguished by Clinical Features or IPI at Diagnosis: a Prospective Population Based Study of the Scotland and Newcastle Lymphoma Group.2008
Professor Stephen Proctor
Dr Jennifer Wilkinson
Dr Tryfonia Mainou-Fowler
Dr Michal Sieniawski
Dr Katrina Wood
et al.
SHIELD - Study of Hodgkin lymphoma in the elderly/lymphoma data base: Progress report2008
Dr Michal Sieniawski
Dr Tryfonia Mainou-Fowler
Dr Jennifer Wilkinson
Dr John Davison
Professor Graham Jackson
et al.
The effect of Diffuse Large B-Cell Lymphoma (DLBCL) treatment regimens on survival: a prospective cohort study [Poster]2008
Dr Tryfonia Mainou-Fowler
Lynne Overman
Dr Katrina Wood
Dr Stephen Crosier
Dr Brian Angus
et al.
A new subtype-specific monoclonal antibody for IAP-survivin identifies high-risk patients with diffuse large B-cell lymphoma and improves the prognostic value of bcl-22007
Dr Tryfonia Mainou-Fowler
Professor Stephen Proctor
CD31 density is inversely related to CD38 expression and predicts for disease outcome in patients with B-cell chronic lymphocytic leukaemia (B-CLL)2006
Dr Tryfonia Mainou-Fowler
Jean Norden
Dr Peter Middleton
Professor Stephen Proctor
Professor Anne Dickinson
et al.
CD31 expression and gene polymorphisms in patients with B-cell chronic lymphocytic leukemia (B-CLL)2006
Dr Tryfonia Mainou-Fowler
Dr Brian Angus
Professor Stephen Proctor
Dr Penelope Taylor
Dr Katrina Wood
et al.
Micro-vessel density and the expression of vascular endothelial growth factor (VEGF) and platelet-derived endothelial cell growth factor (PdEGF) in classical Hodgkin lymphoma (HL)2006
Dr Elaine Willmore
Professor Graham Jackson
Dr Tryfonia Mainou-Fowler
Professor Caroline Austin
Professor barbara Durkacz
et al.
Sensitisation of B-CLL cells to chlorambucil and fludarabine via inhibition of the DNA damage sensor proteins, DNA-PK and ATM2006
Dr Elaine Willmore
Dr Tryfonia Mainou-Fowler
Professor Graham Jackson
Professor barbara Durkacz
Targeting DNA-PK and ATM increases sensitivity to chlorambucil and fludarabine in chemoresistant and p53-defective B-CLL cells2006
Professor Stephen Proctor
Dr Brian Angus
Dr Katrina Wood
Dr Tryfonia Mainou-Fowler
Microvessel density and the expression of vascular endothelial growth factor (VEGF) and platelet-derived endothelial cell growth factor (PDEGF) in classical Hodgkin lymphoma (HL)2005
Dr John Anderson
Dr Stephen Crosier
Lynne Overman
Dr Tryfonia Mainou-Fowler
Dr Sarah Fordham
et al.
Survivin in diffuse large B cell lymphoma: Evaluation as a prognostic marker2005
Dr Tryfonia Mainou-Fowler
Professor Stephen Proctor
Dr Penelope Taylor
Interleukin 4 production by peripheral blood lymphocytes in patients with classical Hodgkin lymphoma2004
Dr Tryfonia Mainou-Fowler
Professor Stephen Proctor
The prognostic value of CD38 expression and its quantification in B cell chronic lymphocytic leukemia (B-CLL)2004
Dr Tryfonia Mainou-Fowler
Dr Penelope Taylor
Professor Anne Dickinson
Professor Stephen Proctor
Intracellular cytokine profiles by peripheral blood CD3(+) T-cells in patients with classical Hodgkin lymphoma2003
Dr Tryfonia Mainou-Fowler
Dr Penelope Taylor
Professor Anne Dickinson
Dr Peter Saunders
Professor Stephen Proctor
et al.
Quantification improves the prognostic value of CD38 expression in B cell chronic lymphocytic leukaemia (BCLL)2001
Dr Tryfonia Mainou-Fowler
Professor Stephen Proctor
Professor Anne Dickinson
Apoptotic activity of gamma linolenic acid (GLA) on normal and malignant cells in B cell chronic lymphocytic leukaemia (BCLL)1998
Dr Tryfonia Mainou-Fowler
Modulation of apoptosis with cytokines in B-cell chronic lymphocytic leukaemia1996
Dr Tryfonia Mainou-Fowler
Effect of anti-apolipoprotein-1 on spontaneous apoptosis of B cells in chronic lymphocytic leukaemia: the role of bcl-2 and interleukin 41995
Dr Tryfonia Mainou-Fowler
Effects of interleukins on the proliferation and survival of B cell chronic lymphocytic leukaemia cells1995
Dr Tryfonia Mainou-Fowler
Interleukin-5 (IL-5) increases spontaneous apoptosis of B-cell chronic lymphocytic leukemia cells in vitrop independently of bcl-2 expression and is inhibited by IL-41994
Dr Tryfonia Mainou-Fowler
Effect of interleukin 4 (IL4) and dexamethasone on the apoptosis and bcl-2 expression in B chronic lymphocytic leukaemia (B-CLL) in culture.1993
Dr Tryfonia Mainou-Fowler
Tumour-associated profiferative responses in vitro of regional lymph node draining solid cancers in man.1989
Dr Tryfonia Mainou-Fowler
Virulence of L monocytogenes genotypes: course of infection in genetically resistant and susceptible mice.1988
Dr Tryfonia Mainou-Fowler
Transferrins and defence against infection1987
Dr Tryfonia Mainou-Fowler
Evidence that transferrin may function exclusively as an iron donor in promoting lymphocytee proliferation1986
Dr Tryfonia Mainou-Fowler
Iron and immunity1986
Dr Tryfonia Mainou-Fowler
Effect of iron deficiency on the response of mouse lymphocytes to ConA: the importance of tranferrin-bound iron1985
Dr Tryfonia Mainou-Fowler
The role of iron and transferrinb in lymphocyte transformation.1983